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 The field of prostate cancer research is in need of biological markers that predict 
which cancers do not need treatment, those that can be treated successfully with a 
localized treatment and more specific cases in which patients are likely to have an 
aggressive form of cancer that will require more aggressive surgical and 
chemotherapeutic treatments.  ZIC2 is one of five members of a family of proteins that 
play critical roles in neural crest and mesoderm growth in normal embryonic brain 
development and in the adult cerebellum of vertebrates. Found throughout the animal 
kingdom, ZIC1-5 genes encode five distinct ZIC proteins containing five highly 
conserved C2H2-type zinc finger motifs, whose structural integrity is important in 
carrying out its function as a transcription factor. We hypothesize that ZIC2 has 
functional significance at the molecular and cellular levels in the initiation of prostate 
adenocarcinoma (PRAD) and the progression to metastatic and/or castration resistant 




regulated by post-translational modifications, such as phosphorylation, ubiquitination and 
sumoylation.  This proposal further outlines the research hypothesis for investigating the 
role of ZIC2 in prostate cancer progression and the effects of the post-translational 
modification, ubiquitination, on the loss or gain of function of ZIC2.   
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        CHAPTER 1 
INTRODUCTION 
 
 The National Cancer Institute’s Surveillance, Epidemiology and End Results 
Program estimates that 180,890 new cases of Prostate cancer and 26,120 deaths in 2016.1  
This equates to a lifetime risk of 15%, i.e., 15 out of 100 men will be diagnosed with 
prostate cancer at some point during their lifetime. However, at least 80% of diagnoses 
have a low-risk of progressing to a life- threatening disease and do not require radical 
chemotherapeutic or surgical intervention. However, due to a lack of prognostic markers 
for disease progression, the majority of these low-risk patients undergo treatments 
leading to significant sexual side effects. The Prostate specific antigen (PSA) test is the 
current and popular screening tool used in medical diagnoses of prostate cancer.2 
However, PSA levels may not always be an accurate indicator of prostate cancer 
development.3  
Current treatment methods for prostate cancer include prostatectomy, hormone 
therapy, radiation therapy, and chemotherapy with the use of sensitive drugs.4 The focal 
point of prostate cancer hormonal treatment is Androgen deprivation therapy (ADT).5 




 Male androgens- testosterone and dihydrotestosterone (DHT) are the main ligands 
for androgen receptor signaling stimulation, the Androgen receptor pathway is a major 
target for prostate cancer treatment due to the ease of depriving the receptor of the ligand 
that is positively transducing a signal once activated. This process allows for the male 
hormones which stimulate healthy and prostate tumor growth to be depleted and then 
restored once the cancer has been annulled.5 ADT as a treatment option and in some 
cases when paired with radiation therapy has had favorable outcomes for patient survival 
but the core issue is the relapse during or after ADT has been discontinue.7 This phase of 
relapse is considered as Castration Resistant Prostate Cancer (CRPC).8 Gene expression 
microarray has identified a number of genes that are significantly up regulated in 
increasing abundance during the multi-step progression model initiating in prostatic 
intraepithelial neoplasia and progressing through CRPC. We reason that these genes are 
likely to play clinically significant roles in predicting disease progression.   
 Among those genes that are up regulated in prostate cancer, is the gene encoding 
the C2H2- zinc finger containing transcription factor, Zic family member 2 (ZIC2). 
Furthermore, an inverse correlation was observed between increased ZIC2 expression 
and decreased expression of Androgen Receptor signaling gene targets in the same data 
set (Figure 1). Additional RNAseq information has provided similar results for ZIC2 in 
PCa. The Cancer Genome Atlas data shows a comparison of normal to cancer with ZIC2 





Figure 1. ZIC2 and Androgen receptor are observed to have contrasting expression in bioinformatics 
analysis. 
Source: Adapted from Tomlins, S. A.; Mehra, R.; Rhodes, D. R.; Cao, X.; Wang, L.; Dhanasekaran, S. M.; 
Kalyana-Sundaram, S.; Wei, J. T.; Rubin, M. A.; Pienta, K. J., Integrative molecular concept modeling of 
prostate cancer progression. Nature genetics 2006, 39 (1), 41-51. 
 
 Tomlins et al. utilized a bioinformatic approach to classify genes associated with 
prostate cancer.9 The outcome of the integrative analysis was also profiled against 
increasing histological grades of prostate cancer. The tumor grade analysis expanded 
from benign prostatic hyperplasia to metastatic prostate cancer. There was a significant 
correlation exhibited through little to no expression of ZIC2 and increasing with 
progression of worsened disease status. Additional RNAseq information has provided 
similar results for ZIC2 in prostate cancer. TCGA data shows a comparison of normal to 
cancer with ZIC2 being highly upregulated in prostate adenocarcinoma. The overall 




Prostate Cancer. Thus, reduced expression of ZIC2 will negatively affect cell 
proliferation and disrupt other hallmarks of cancer.  The following objectives have been 
identified to test the hypothesis:  
Objective 1: To characterize the functionality of ZIC2 with the implementation of 
CRISPR-Cas9; our lab has characterized steady-state expression among varying prostate 
cancer cell line models. Moving forward, it is our goal to characterize the functionality of 
ZIC2 following a forced knockout using CRISPR-Cas9 vectors.  
Objective 2: To assess the metabolic activity after ZIC2 CRISPR-Cas9 gene 
editing in PC-3 cells; cellular metabolism is a signature in cancer models and a 
preference between cellular respiration and fermentation is a distinct indication of cancer 
suppression or promotion. 
Objective 3: To determine the stabilization activity of post-translational 
modifications on ZIC2; to date, ZIC2 has been reported to be phosphorylated. It is our 
goal to alleviate the effects of ZIC2 on prostate cancer progression, discovered in 









 ZIC family member 2 is one of five members that make up the family of ZIC 
proteins (Figure 2).10-11 The entire ZIC family comprises transcription factors that have 
been reported to play various roles in neuronal and embryonic development.10, 12-13 Each 
ZIC family member has five zinc fingers that with the C2H2 motif.14 The zinc finger 
domains allows for DNA binding and protein-protein interactions.15 ZIC family members 















Figure 2. Structural differences of the Zic family members when comparing ZIC2. 
Source: Adapted from Houtmeyers, R.; Souopgui, J.; Tejpar, S.; Arkell, R., The ZIC gene family encodes 
multi-functional proteins essential for patterning and morphogenesis. Cellular and molecular life sciences: 




 Mizugishi et al. elucidated a protein-protein interaction between ZIC2 and other 
regulatory transcription factors, such as GLI family zinc finger proteins.11 The predicted 
molecular weight of ZIC2 is 55kDa. Our results indicate a difference in molecular weight 
(65kDa), which suggests the occurrence of post-translational modifications.   
The ZOC motif was identified as a regulatory domain and the responsible binding 
location interacting with I-mfa (now referred to as MyoD family inhibitor, MDFI).16 
Binding of MDFI to ZIC2 occurred at the N-terminus of ZIC2 and caused inhibition of 
ZIC2 transcriptional activity. An additional common structural characteristic amongst the 
family members is the Zinc finger N-terminally conserved domain (ZF-NC).13 This 
domain is immediately upstream of the zinc fingers and its approximate length is 14-21 
amino acids.13   
ZIC2 has been implicated in a wide variety of embryonic development processes: 
neurulation, gastrulation, body pattern formation, axon guidance, and forebrain 
development.13-14, 17-19 During brain development, a mutation in ZIC2 promotes, 
Holoprosencephay, abnormal forebrain development.20 Holoprosencephaly (HPE) is a 
disease in which the brain forms into a unilateral organ instead of the normal left and 
right hemispheres.21-23  
ZIC2 occupies a specific region on the 13q chromosome. Deletions and 
duplications of chromosome 13 have been reported to contribute to HPE. Brown et al. 
reported 16 mutations with in a group of HPE patients.21 Within this study, mutations 
#10-#16 emphasize a common alanine tract expansion. An additional group of 7 




also contains two histidine tracts near the N-terminus. The most impactful histidine tract 
possesses 9 residues. Dubourg et al. identified ZIC2 mutations leading to HPE in 200 
patients.24 Seven mutations within the cohort were identified specifically related to ZIC2. 
Within the seven, two of the mutations consisted of poly-histidine tract polymorphisms. 
One of the tracts lacked a histidine leading to eight histidine residues while the other tract 
contained an additional histidine, leading to ten residues. The histidine tract 
polymorphisms within ZIC2 have been linked to neural tube defects.  
ZIC proteins are hypothesized to regulate transcriptional activity via direct DNA 
binding.25 Sakurada et al. investigated the proteins from rat brain nuclear extracts 
responsible for activation of the Ca2+/calmodulin-dependent protein kinase II (α-Cam 
kinase II) promoter.26 Construction of a cDNA library of brain extracts identified ZIC2 as 
a binding protein. The activity of the α-Cam kinase II promoter was up-regulated  up to 5 
fold in cultured neuronal cells by ZIC2.26  
Aside from direct DNA binding, ZIC family members can function as co-factors 
through the formation of complexes with other transcription factors and proteins.15, 27-28 
Aruga et al. investigated the transcriptional activation of two complexes that were ZIC2 
dependent.15 Complex I was a compilation of a DNA dependent protein kinase catalytic 
subunit (DNA-KPCs), Ku70/80, and poly (ADP-ribose) polymerase;   DNA KPCs and 
Ku70/80 are collectively responsible for double strand break repair. The Complex II 
consisted of Ku70/80 and RNA helicase. Results showed that both complexes depend on 
ZIC2 for DNA binding upstream of the target gene promoter. Salero et al. reported on 




library was constructed of human brain samples. The library data was a partnership 
between other assays, which included yeast one hybrid system, Electromobility shift and 
luciferase reporter activity to confirm the transcriptional activation of three binding sites 
for ZIC family members 1 and 2. The binding sites within the Apolipoprotein E (ApoE) 
promoter were concluded to be a consensus nucleotide sequence-CTG followed by a GC-
rich region. ApoE is an important protein in transport and metabolism of plasma 
cholesterol and triglycerides.  
Pan et al. identified ZIC2 and other family members to have influential roles in 
regulating Myogenic factor 5 (Myf5).27 During embryonic development, Myf5 and other 
myogenesis proteins give support to muscular tissue formation. A myogenic protein can 
be inhibited specifically by inhibitor of MyoD family (I-mfa) protein. Mizugishi et al. 
demonstrated the ability of I-mfa to act as a transcriptional repressor to ZIC2.16 The 
repressor activity of I-mfa disrupts nuclear translocation of ZIC2 and restricts it to the 
cytoplasm. This repression is achieved via N-terminus binding of ZIC2 to the C-terminus 
of I-mfa.  I-mfa inhibits nuclear localization of ZIC 1, 2 and 3.  
Cell fate determination, motility, and organogenesis can be regulated by way of 
canonical and non-canonical Wnt signaling.30 Pourebrahim et al. reported ZIC2 as a 
regulator of the β-catenin-TCF4 complex.28 In canonical Wnt signaling β-catenin is 
activated and retained in the cytoplasm. The TCF proteins aid in the translocation of β-
catenin to the nucleus. ZIC2 was shown to bind to TCF4 via the DNA binding high 




mRNA expression of ZIC 1, 2, and 5 have been  identified in meningiomas and 
other brain tumors, such as medullablastoma and glioblastoma.31 Previous research of rat 
brain development has categorized ZIC family members to be required for cell 
proliferation and differentiation of meningeal progenitor cells. Meningiomas are primary 
tumors of the central nervous system. RT-PCR and microarray data confirmed higher 
expression of ZIC2 meningiomas. Thus, concluding that ZIC2 is a potential novel 
molecular marker for meningiomas.   
Marchini et al. investigated a role for ZIC2 in epithelial ovarian cancer.32 ZIC2 
mRNA was expressed more in the malignant tumors of epithelial ovarian cancer 
compared to those with low malignant potential. It was concluded that ZIC2 may be a 
distinguishable candidate for helping to identify tumor outcomes in epithelial ovarian 
cancer.  In an effort to further classify ZIC2 as an oncoprotein, we hypothesize a role for 
ZIC2 in migration and invasion of tumor metastasis modeled by in vitro experimentation.  
ZIC2 knockdown impaired the dispersion and migration of Cajal-Retzius cells into the 
cortical layers of embryo forebrain.33 Chan et al. explored the relationship between ZIC2 
and GLI1 in cervical cancer cells.34 Overexpression of ZIC2 in cervical cancer cells 
increased cell proliferation, hedgehog signaling activity and anchorage-independent 
growth ability. Additionally, siRNA mediated ZIC2 knockdown induced cell apoptosis 
while ZIC2 overexpression enhanced proliferation in pancreatic cancer cells.35 In totality, 
these studies contribute to growing knowledge of a role for ZIC2 in proliferation, 




In this age of personalized medicine where unique genetic alterations are touted as 
potential therapeutic targets, there is still the common observation, first reported by Otto 
Warburg, that most cancer cells produce energy by high rates of glycolysis followed by 
lactic acid production, instead of lower rates of glycolysis followed by oxidation of 
pyruvate in mitochondria as in most differentiated cells.36-37 Aerobic glycolysis yields 
less ATP per glucose molecule. However, it is the preferred energy metabolism used by 
cancer cells that need to generate many intermediate metabolites from glucose for cell 
growth and do not want to oxidize glucose completely to CO2. Warburg hypothesized 
that mitochondrial dysfunction itself was the cause of cancer.38 Currently this has been 
replaced with the idea that mutations to oncogenes and tumor-suppressors are the cause 
of cancer and that Warburg’s observations were merely an effect. However, many 
experiments continue to support the notion that cancer can be treated by increasing 
mitochondrial oxidative phosphorylation.   
 Mitochondria are the energy control center of the cell.39 The ATP production for 
continued cellular activity is generated by glycolysis and oxidative phosphorylation. The 
electron transport chain resides within the inner membrane of the mitochondria and 
oxygen begins the proton exchange throughout complexes I, II, III, IV, and V (Figure 3).  
Glycolysis, the process of breaking down glucose, yields pyruvate for entry into the citric 
acid cycle.8 Pyruvate oxidation generates the bulk of ATP molecules necessary for 





Figure 3. The process of electron transfer in the electron transport chain.  
Source: Adapted from Biochemist01 Archives Page. https://biochemist01.wordpress.com/tag/electron-
transport-chain/ (accessed Oct 4, 2015). 
             
The Warburg effect is an energy generating process that supports glycolysis to 
feed into lactic acid fermentation in the cytosol.  Aerobic glycolysis yields less ATP 
molecules for energy usage however it is the preferred energy metabolism way of life for 
cancer cells. The mitochondrial dysfunction within cancer cells is an escape mechanism 
to avoid apoptotic triggers.40-41 Mitochondrial dysfunction has been reported in several 
disease models including cancer and neurodegenerative disorders.40, 42-47 In an effort to 
perpetuate invasiveness and continued cell divisions, the metabolic transformation is 
useful for generating energy as a means of maintenance. The Warburg effect is the 
metabolism process cancer cells utilize to survive in low-oxygen, hypoxic, conditions, 
shown in Figure 4. This process is preferred over the alternative-oxidative 




hypoxic environment by producing excess amounts of reactive oxygen species (ROS).48
 
Figure 4. Comparison of ATP production in normal and cancer cells. 
Source: Adapted from Metabiolab. http://metabiolab.com/about-6/technologies-suite/ (accessed Sept 20, 
2015). 
  
 Kloss-Branstatter et al. evaluated somatic mutations associated with several genes 
encoded by the mitochondrial DNA contributing to prostate cancer tumor progression 
and elevated PSA levels.49 Ling et al. performed a compelling study in human H460 non-
small cell lung cancer cells to identify the role of mitochondria in Bortezomib induced 
apoptosis.50 H460 cells were treated with Bortezomib, an anti-tumor drug and inhibitor of 
the 26S proteasome activity.  Within 24 hours of treatment, increased ROS production, 
increased mitochondrial membrane potential and release of cytochrome c were observed 
supporting a role for Bortezomib in restoring mitochondrial mediated apoptosis.  
Kaipparettu et al. used cytoplasmic hybridization to study the effects of mitochondria 




osteosarcoma cells.47 The introduction of mitochondria from benign breast cells into 
osteosarcoma cells reinstated respiratory chain activities and elevated ATP synthesis, 
whereas mitochondria from breast cancer cells did not. The same lab has shown that 
while the presence of mitochondria in the osteosarcoma cells is essential for tumor 
formation in mice, the introduction of mitochondria with mild mutations conferring 
varying levels of reduced oxidative phosphorylation activity lead to correlated levels of 
tumorigenicity potential. Proto-oncogenes can be strategically controlled by DNA 
mutations. The DNA mutations strongly influence roles for proto-oncogenes in cancer 
progression. Oncoproteins are a category of proteins that continue cancer progression.  
Similar to mutations of proto-oncogenes, post-translational modifications 
influence the function of oncoproteins. PTMs can stimulate aberrant expression, function, 
and cellular drug resistance within a biological system. Two post-translational 
modifications have been linked to ZIC2. Phosphorylation is reported to aid in 
maintaining the role ZIC2 in the aforementioned protein complexes, investigated by 
Ishiguro et al.15 Further work into the role of the DNA-PKcs exhibited how ZIC2 is 
modified.  To identify the targeted site for phosphorylation, N-terminally truncated 
constructs were used for experimentation. Investigative evidence suggested that the site 
of phosphorylation of ZIC2 is Serine-200 by DNA-PKcs. 
Two post translational modifications of interest for this study are sumoylation and 
ubiquitination. Lysine residues are essential components of both PTMs. Ubiquitination is 
a controlled process resulting in the attachment of a single Ub protein (mono-




ubiquitination are activation, conjugation, and ligation. Activation of Ub is accomplished 
with catalysis of an E1 activation enzyme.  Ub conjugation relies on the E2 conjugation 
enzyme for transfer to E3 ligating enzyme. The E3 ligase identifies the substrate and site 
of attachment and performs the ligation of Ub to protein substrate. The complete amino 
acid structure of ZIC2 provides a further depth of post-translational modifications 
 (Figure 5).  
 
 
Figure 5. Amino acid sequence features of ZIC2. 
   
There are two Lysine residues, which are located upstream of the zinc fingers at 
positions 61 and 253. Using a sumoylation prediction site, Lysine 253 was the only 
outcome for expected post-translational modification by sumoylation. Sumoylation  is the 
process of the attachment of a small ubiquitin like modifiers, SUMO-1, SUMO-2, or 
SUMO-3.51-52 A SUMO group is attached to its substrate through steps of enzymatic 











Key: S,phosphorylated Serine   K,Lysine upstream of Zinc fingers 
 
  XXXXXX,antibody binding region   XXXXXXX,Zinc Fingers 
 




attachment to Sumoylation Activating enzyme (SAE, also known as, E1). 51A transfer 
occurs between E1 and E2.51 E2 is the conjugating enzyme, Ubc9.51 E3 ligases are 
responsible for facilitating the sumoylation event and efficient attachment to the 
substrate.51 A group of PIAS proteins comprise one of the E3 ligases used for that 
process(Figure 6).52   
 
Figure 6. The post-translational modification, Sumoylation: (A) Sumoylation prediction results for Lysine 
residues upstream of zinc fingers at position K61 and K253. (B) Sumoylation process of attachment to 
protein substrate. 
Source: Adapted from Creton, S.; Jentsch, S. Cell 2010, 143 (5), 848–848. 
 
The consensus site for sumoylation is Ψ-K-X-D/E.51-53 This sequence of four 
residues is comprised of a hydrophobic amino acid (Ψ), a lysine, any amino acid, and 
concludes with a glutamic or aspartic acid residue. The predicted site of sumoylation for 







Chen et al. has investigated the sumoylation activity of ZIC3.54  ZIC3 represses 
the gene promoter of cardiac α-actin. At the lysine 248 residue of ZIC3, a mutation to 
arginine was made and repressor activity was eliminated due to consensus site mutation 
for targeted sumoylation. The ubiquitination process flows into the 26s proteasome 
degradation pathway (Figure 7).  De-ubiquitinating enzymes can reverse ubiquitination 
by cleaving Ub from the protein substrate. 
 
 
Figure 7.  The post-translational modification, Ubiquitination: (A) Ubiquitination prediction results for 
Lysine residues upstream of zinc fingers at position K61 and K253. (B) Ubiquitin cycle and protein 
degradation process after substrate  attachment. 
Source: Adapted from BostonBiochem. http://www.bostonbiochem.com/products/ubiquitin (accessed Dec 
28, 2015). 
 
These modifications, in some instances, provide a necessary component to 
facilitate degradation.51 The E3 ligase groups of proteins within eukaryotic systems are 
HECT, RING, and U-box proteins.55 Within the RING group, RNF180 is an E3 ligase 
reported to interact with ZIC2.56 The TCGA and cBioPortal information provides mRNA 
expression of RNF180 when compared to ZIC2 in benign and cancer samples of the 





expression to ZIC2 in benign and cancer samples. SPOP was determined to be the most 
frequently mutated gene in 112 normal and prostate tumor samples.58 
                
Figure 8.  Bioinformatic analysis of RNF180 mRNA expression. (A) Data obtained from The Cancer 
Genome Atlas. (B) Data obtained from CBIOPortal.  
 
SPOPL was incorporated in this analysis due to the heterodimeric formation with 
SPOP.59 From the PRAD dataset, RNF180 was reported to have the highest amplification 
frequency in Neuroendocrine Prostate Cancer (NEPC). RNF180 was also reported to 
have deletions and mutations in a variety of Prostate cancer studies. In gastric cancer, 
RNF180 has been reported to be epigenetically silenced.60-61 The epigenetic control could 
be problematic in the role of RNF180 in our PC-3 model in relation to aberrant 
expression of ZIC2.  
It is proposed that ZIC2 is involved in prostate cancer progression and may be 





during prostate cancer progression?  In this study, we provide evidence in which the 
aberrant expression of ZIC2, that is not post-translationally modified and degraded, 








MATERIALS AND METHODS 
 
3.1       Mammalian Cell Culture 
PC-3 prostate cancer cell line were obtained from ATCC and cultured at 37 °C, 
5% CO2 in Dulbecco's modified Eagle's medium/F-12 mixed media (Gibco) 
supplemented with 100 units/ml penicillin, 100 mg/ml streptomycin (Corning) and 10% 
fetal bovine serum (Atlanta Biologicals). Stable overexpressing cell lines were 
transfected with 2µg of Empty-MYC or ZIC2-MYC vector (PE and PZ notations) in 
OptiMEM media. After 72 hours, the cells were maintained in 1mg/ml or 1.5 mg/ml 
G418 (EMD Millipore).  
 
3.2 CRISPR-Cas9 Gene Editing 
Targeted ZIC2 gene editing was achieved by transfecting 1x106 PC-3 cells in   
OptiMEM media using a 3 microliter to 1 microgram ratio of Fugene 6HD transfection 
reagent and the DNA 2.0 CRISPR-Cas9 plasmid pD1301-AD:154471 containing the 20-
mer single guide RNA 5’-GAAGGCTCCCATGTGCGCGG-3’.  This sequence is 
complementary to the coding nucleotides 161 to 180 in the first exon of the ZIC2 NCBI 





conditions and then sorted by GFP fluorescence into single colonies by Fluorescence 
activated cell sorting (FACS) into a 96-well plate.  Single cells were cultured for 
approximately two months to achieve confluency.  Individual cell lines were then 
expanded and used for experimentation.   
 
3.3 Proliferation 
For cell growth experiments, 1x104 cells were plated in triplicates of 6-well 
culture dishes. At the respective time courses, cells were obtained using 200μl of 
Trypsin/EDTA and diluted in 300μl of DMEM/F-12 media and counted using a 
Nexelcom cell counter.  
 
3.4 Real Time Quantitative PCR 
RNA was obtained from cells using the E.Z.N.A. RNA isolation kit (Omega 
Biotek) according to manufacturer’s protocol. Complementary DNA was generated from 
2μg of RNA and used for RT-qPCR. Taqman probes( Assay ID: Hs01120965_m1 and 
Gene Symbol: TMPRSS2, hCG401238; Assay ID: Hs01060665_g1and Gene Symbol: 
ACTB, hCG15971;Assay ID: Hs01103582_s1 and Gene Symbol: JUN, hCG1780282; 
Assay ID: Hs00233992_m1 and Gene Symbol: MMP13, hCG39650; Assay ID: 
Hs00158486_m1 and Gene Symbol: KISS1, hCG96217; Assay ID: Hs00171105_m1 and 
Gene Symbol: CCNA1, hCG32831; Assay ID: Hs02596866_g1 and Gene Symbol: MT-
CO3, MYBPC3, SLC12A1; Assay ID: Hs00951307_m1 and Gene Symbol: DKK3, 






3.5 Transient Transfections 
To determine whether sumoylation both PTMs are required for ZIC2 stabilization, 
transient transfections in PC-3 cells was performed using the following plasmids: ZIC2-
Myc-DDK, ZIC2- K61R-Myc-DDK, ZIC2-K253R-Myc-DDK, and ZIC2 K61R– K253R 
-Myc-DDK. An empty vector control was also used for transfection.     After 48 hours, 
cell extracts were used for experimental analysis.  
 
3.6 Migration and Invasion  
Collagen coated 8.0μm transwell inserts were assembled into a 24-well plate and 
cell deposits of 3x104 were allowed to migrate for 5 hours. For invasion assays, 1x105 
cells were allowed to invade 50μl of Matrigel (Corning) concentrated at 250μg/ml in 
8.0μM transwell inserts. Cellular invasion was assessed after 24 hours with a 5% 
complete media chemoattractant. For both assays, cells were suspended in serum-free 










 To address our hypothesis we have firstly evaluated whether or not ZIC2 is 
expressed at steady state levels within a select group of Prostate cancer cell lines. The 
predicted molecular weight of ZIC2 is 55kDa. In order to establish in vitro models of 
ZIC2 expression on prostate cancer, we also probed for ZIC2 expression in various 
human prostate cancer cell lines (Figure 9).  We chose a sample of cells lines 
representing both ethnicity and Androgen receptor (AR) status.   E006AA is a primary 
AR positive, African American prostate cell line and E006AA-hT is a highly tumorigenic 
subline.62  LNCaP is also an AR positive cell line of Caucasian origin.63  DU145 
represents an AR negative cell line while PC-3 represents an AR negative and highly 
aggressive cell line model.64-65  All prostate cancer cells examined by immunoblot 
express a common ZIC2 band that runs just above 65 kDa.  Androgen receptor (AR) 
positive cell lines (E006AA, E006AA-hT, and LNCaP) also express a lower ZIC2 band 






                   
Figure 9.  ZIC2 is expressed in human prostate tissue and prostate cancer cell lines. (A) ZIC2 mRNA 
expression analysis in cancer (blue) and benign samples (pink). Prostate adenocarcinoma dataset from the 
Cancer Genome Atlas using Illumina HiSeq throughput, N=550. (B) ZIC2 is expressed in several Prostate 
cancer cell lines.  
 
4.1 Genome Edited ZIC2 Knockdown with CRISPR-Cas9 
 In order to determine if ZIC2 contributes to aggressive prostate cancer cell 
growth, we subjected the PC-3 cell line model to CRISPR-Cas9 gene editing of ZIC2.   
CRISPR-Cas9 gene editing was successfully performed with the single guide RNA 118 
that spans coding nucleotides 161 to 180 in the first exon of the ZIC2 NCBI Reference 
Sequence: NM_007129.  Clonal cell lines resulting from single cell sorting of edited cells 
were evaluated for ZIC2 alterations at both the DNA sequence and protein expression 
levels. Three reads from each allele revealed 1 and 2 bp deletions at position 163 of the 
ZIC2 mRNA NCBI Reference Sequence: NM_007129.3 (Figure 10).  No parental reads 
were recovered from this edited cell line. The karyotype of the parental PC-3 cell line has 
previously been reported by multiple laboratories as being diploid at Chromosome 











Figure 10. CRISPR-Cas9 Loci of sgRNA targeting ZIC2. Nucleotide (upper) and amino acid (lower) 
alignments of the ZIC2 coding region mutated by CRISPR/Cas9 gene editing in PC-3.  The black box 
indicates the codon “GCG” coding for Alanine in the parental/ “wild type” ZIC2.  One edited allele 
contains a single “G” nucleotide deletion at coding nucleotide 163 resulting in a frameshift mutation of 
Alanine (A) to Arginine (R) at amino acid position 55.  The other allele contains a “GC” dinucleotide 
deletion at coding nucleotides 163 and 164 resulting in a frameshift mutation of Methionine to Glycine at 
amino acid position 57. 
 
 Therefore, we hypothesize that we have created a homozygous null allele for the 
full length ZIC2 protein in the PC-3 cell line, hereafter referred to as PC-3 ZIC2 -/-.    
One clone (shown in culture in Figure 11), that we named according to the Human 
Genome Variation Society (HGVS) guidelines as PC-3 
NM_007129.3(ZIC2):c.[163delG;163_164delGC], contained mutations at two alleles.2 
These alleles were confirmed in this cell line by identification of at least three identical 
Sanger sequencing reads from cloned genomic DNA PCR products spanning the first 




           
 
Figure 11. Phenotype of wild-type and CRISPR-Cas9 mutant cells. Microscopic brightfield images of  
PC-3 parental cells and PC-3 ZIC2 -/- cells.   
 
 Western blot analysis confirmed that ZIC2 protein levels in PC-3 ZIC2 -/- cells 
were indeed altered when compared to the PC3 ZIC2 parental cell line using the rabbit 
monoclonal antibody (Figure 12).    
  
Figure 12. Western blot of ZIC2 protein expression in PC-3 parental and PC3 ZIC2 -/- edited cells. WT 
and mutant immunoblot analysis of ZIC2 expression. (A) Differential expression among mutations after 
CRISPR Cas9 editing in PC-3 cells. (B) Stable overexpression in PC-3 +ZIC2 (PZ). E denotes empty 
vector control (PE). 
 
4.2 ZIC2 Knockdown Impairs Cellular Proliferation 
 To initially characterize the phenotype of the PC-3 ZIC2 -/- cells, we first 
performed cell proliferation assays in the form of growth curve analyses.  As early as day 





five, ZIC2 -/- cells exhibited a significant decrease in cell growth when compared to the 
parental PC-3 cells and this difference expanded to a nearly 5-fold decrease by day seven 
(Figure 13).   This data provides the first functional evidence supporting a role for ZIC2 
in the promotion of prostate cancer cell growth.   
 To assess the influence of mutagenesis, we evaluated cellular growth in the PC-3 
ZIC2 -/- cells as well as the stably overexpressed cells. PC-3 ZIC2 -/- cells grew 
approximately 5 times slower than the PC-3 parental cells within one week. The doubling 
time of PC-3 cells has an effect on the growth throughout the time course which 
influences the significant differences between PC-3 and PC-3 ZIC2 -/- cells at day 5.  
Furthermore, in stably overexpressed PZ cells, we observed PZ cells growing twice as 
fast as the empty vector control. This data provides evidence of ZIC2 influencing cellular 
proliferation in a prostate cancer model. The growth rate differences amongst the PC-3 
WT and PE are distinguishable by the G418 stably selected PE cells. G418 resistance has 
been linked to metabolic kinetics of the enzyme-ADP complex.66 The cellular 






Figure 13. Proliferation growth curves for mutant cell types. Growth analysis of PC-3 cells exhibit 
significant growth differences with the knockdown cells.  PC-3 cells exhibit significant growth differences 
with the knockdown cells showing slower while the PZ cells grow faster than the empty vector control.  
 
4.3 ZIC2 Knockdown Hinders S Phase Entry of Cell Cycle 
 After detailed evaluation of PC-3 proliferation, we explored the cell cycle phase 
that supports the cell growth differences PC-3 ZIC2 -/- cells demonstrates a greater phase 
within G0/G1compared to PC-3 WT. This data supports the proliferation analysis due to 
the absence of cell cycle arrest. Our results indicate a potential role for ZIC2 in the 
control of cell cycle but not a direct arrest. The overexpressed model did not have a 
significant observation in cell cycle phases associated with replication and division 
although there was an observation of increased cell growth. After evaluation of cell 
proliferation, we performed cell cycle analysis of the  
PC-3 ZIC2 -/- cells by flow cytometry of propidium iodide (PI) stained cells (100K).  
When compared to parental PC-3 cells, we found an increased percentage of ZIC2 -/- 
cells in G1 (57% in PC-3 ZIC2 -/- ; 39% in PC-3), indicating a sizeable G1 arrest in the 





Figure 14. Cell cycle analysis of PC-3 cells Cell cycle analysis of PC3 -/- cells and PZ cells. Flow 
cytometry analysis of cells was measured using 100,000 events. 
 
4.4 ZIC2 Deters Migration and Invasion in Mutant PC-3 Cells 
 More detailed investigations of functional analysis yielded information leading to 
the influence of ZIC2 in migration and invasion of PC-3 cells. To date there have not 
been studies relating ZIC2 to migration and invasion in a prostate cancer model (Figure 
15). Due to our evidence of ZIC2 knockdown severely decreasing cellular proliferation, 
we also wanted to determine the transwell migration and Matrigel invasion potential of 
mutant and stably overexpressed PC-3 cells. PC-3 ZIC2 -/- cells demonstrated slower 
migration while the PZ cells did not significantly have altered migratory effects. Matrigel 
invasion of PC-3 ZIC2 -/- cells also demonstrate decreased invasiveness will PZ cells 
exhibited a significant increase in invasion. These results suggest a role for ZIC2 in 
prostate cancer cell migration and invasion.  This is significant due to the overall 







Figure 15. ZIC2 is required for proper migration and invasion. Migration and invasion cell counts were 
normalized to the WT and empty-vector controls. Nuclei images below each graph are representative from 
an analysis of N=3 independent experiments.  Error bars are represented as +SEM. p-Value notation is 
denoted as N.S. =not significant; *=p<0.05; **= p<0.01; ***=p<0.001 
 
4.5 RNA-Seq of PC-3 ZIC2 -/- Cells  
 ZIC genes are most closely related to the GLI family of transcription factors that 
are downstream effectors of the Hedgehog signaling pathway. Therefore, we reasoned 
that ZIC2 may in part play a role in promoting the aggressive phenotype of PC-3 by 
transcriptional regulation.  In order to reveal the transcriptome changes in PC-3 ZIC2 -/-, 
we performed RNASeq on total RNA from PC-3 ZIC2 -/- and PC-3 parental cells.  
Sequencing of rRNA depleted and random-primed cDNA from PC-3 parental cells 
yielded 19,938,569 uniquely mapped reads, whereas the PC-3 ZIC2 -/- cells yielded 




were identified using cuffdiff with a threshold of p<.05 and a greater than 2-fold change 
in gene expression. We report a short list of identified DEGs in Table 1.   
Table 1. RNA Sequencing Results of Differentially Expressed Genes in PC-3 ZIC2 -/- Cells 
 
 We verified a subset of these DEGs by quantitative reverse transcription 
polymerase chain reaction (qRT-PCR), as shown in Figure 16.  To validate genes related 
to proliferation, migration and invasion we chose MMP13, CCNA1, JUN, KISS1 and 
DKK3 for analysis.  Our results confirmed that pro-growth genes such as CCNA1, JUN 
and MMP13 were down-regulated in PC-3 ZIC2 -/- cells and that genes associated with 
cell differentiation or tumor suppressor activity including KISS1, DKK3 and TMPRSS2 
were upregulated in PC-3 ZIC2 -/- cells.  These results further support a role for ZIC2 in 





Figure 16. qRTPCR Gene expression confirmation from RNA sequencing results of several genes linked to 
up regulation and downregulation in ZIC2 knockdown PC-3 cells. RNA sequencing revealed several genes 
associated with down/up regulation.  
 
4.6 Cancer Cell Metabolism Genes 
 Warburg established that even in the presence of oxygen, cancer cells display an 
increase in glycolysis and lactic acid production along with reduced levels of 
mitochondrial oxidative phosphorylation. We present RNA sequencing results of 
differentially expressed genes linked to energy metabolism in Table 2. Consistent with 
PC-3 performing high rates of glycolysis, the sugar/H+ symporter SLC2A13, is expressed 
at high levels in PC-3 and significantly decreases in PC-3 ZIC2 -/- cells.  Although not 
significant, key genes involved in glycolysis including PGK1, ENO1, ENO2 and ENO3 
are also downregulated in the PC-3 ZIC2 -/- cells. Conversely, genes involved in 
mitochondrial oxidative phosphorylation, such as the mitochondrial MT-CO3 are 
expressed at significantly higher levels in the PC-3 ZIC2 -/- cells.  We confirmed the MT-




ZIC2 -/- cells include MT-ATP6 and MT-ATP8 suggesting increased mitochondrial ATP 
production.  The cancer stem cell marker, CD44, has recently been shown to promote 
glycolysis in PC-3 cells.68  PC3 ZIC2 -/- cells show significantly decreased CD44 
expression when compared to PC-3 parental cells.    
Table 2. RNA Sequencing Results of Differentially Expressed Genes Linked to Energy Metabolism in 
PC-3 ZIC2 -/- Cells 
Gene Gene Name  
Log2 
Fold Change p-Value 
SLC2A13 Solute Carrier Family 2 Member 13 -2.684 0.015 
CD44 CD44 molecule (Indian blood group) -1.997 0.0112 
ENO2 Enolase 2  -1.372 0.660 
PGK1 Phosphoglycerate Kinase 1 -1.236 0.251 
ENO3 Enolase 3  -1.180 0.250 
ENO1 Enolase 1  -0.802 0.393 
MT-ATP6 Mitochondrially Encoded ATP Synthase 6 0.978 0.657 
MT-ATP8 Mitochondrially Encoded ATP Synthase 8 1.248 0.733 
MT-CO3 
Mitochondrially Encoded Cytochrome C 
Oxidase 3 1.567 0.022 
MT-CYB Mitochondrially Encoded Cytochrome B 1.568 0.073 
 
 Additional evidence indicating increased metabolic activity in the mitochondria of 
PC-3 ZIC2 -/- cells was shown by an unexpected increase in the metabolic activity as 
measured indirectly by increased MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-




assay.69  PC-3 ZIC2 -/- cells display significantly higher MTS assay levels as indicated 
by the increased relative fluorescence when compared to PC-3 parental cells. 
  
 
Figure 17. Metabolic characterization of PC-3 ZIC2 -/- and ZIC2 rescued cells. (A) Up-regulation of MT-
CO3 in ZIC2 knockdown is recovered with stable re-expression of ZIC2. (B) Cell proliferation of rescued 
phenotype. -/-E is abbreviated for mutant transfected with empty control and -/-Z is abbreviated for mutant 
transfected with ZIC2.  This graph represents rescued growth of PC3 ZIC2 -/- cell with ZIC2 insertion.(C) 
ZIC2 indirectly affects cellular metabolism switch via initiation of oxidative phosphorylation.(D) 







4.7 Rescue of ZIC2 Edited Cells  
 In order to provide evidence that the CRISPR-Cas9 gene editing in PC-3 cells 
was specific for ZIC2 and to determine whether the phenotypes induced in the edited 
cells could be rescued, we stably re-expressed a full length ZIC2 ORF in the PC-3  
ZIC2 -/- cells.  We measured cell proliferation by growth curve analysis and found that 
increased proliferation in these cells was recovered. MT-CO3 mRNA levels were 
measured by qRT-PCR and shown to significantly decrease in the ZIC2 rescued cell line. 
Finally, in order to test whether energy metabolism had been affected by ZIC2 re-
expression, the MTS assay was performed on the rescued cells.  The results shown in 
Figure 17 indicate the MTS assay product, formazan, was also significantly reduced in 
the presence of increased ZIC2 protein expression. We measured ZIC2 protein levels by 
immunoblot analysis and confirmed increased expression of ZIC2 in the rescued cell 
lines. In combination, our results from the ZIC2 rescued cell line indicate a reversal 
towards the original PC-3 cancer cell phenotype. 
4.8 Ingenuity Pathway Analysis of Potential Roles for ZIC2  
4.8.1 Migration and Invasion  
 RNA sequencing data was the input for IPA to generate specific models 
implicating ZIC2 in cell cycle progression, metabolism, and metastatic potential. The 
canonical pathway addressing cellular metastasis overlapping with significant genes from 
our dataset reveals alternating pathways for impacts in cell migration. One pathway 
implicates Wnt signaling and downstream targets: PKA, β-catenin, TCF/LEF to 




pathway abbreviates migration and invasion through the ERK pathway and angiogenic 
regulation by the FOS and JUN dimerization and VEGF (Figure 18).  
 
Figure 18. Metastatic pathway implicating expression of several genes up and downregulated as a result of 
ZIC2 knockdown. 
 
4.8.2 Cell Cycle Analysis  
 Cellular proliferation and division is controlled in a very detailed manner. Figure 




component of the cell. G1/S phase transition is reported to be affected by p27. 
 
Figure 19. Cell cycle pathway identifying altered gene expression from RNAseq results in every phase. 
 
4.8.3 Mitochondrion Metabolism  
 Oxidative phosphorylation is a metabolic process used to generate ATP molecule 
utilized for cellular energy. Cancer cells utilize the expensive Warburg effect rendering 
the mitochondria inactive. The importance of ZIC2 regulating a switch from glycolysis to 
increased oxidative phosphorylation has been implicated by upregulating MT-CO3 
(Figure 20). MT-CO3 directly interacts with HIF1-α and SLC25A13, reported by IPA 






Figure 20. Oxidative phosphorylation pathway to highlight upregulation of MT-CO3. 
 
4.9  Re-introduction of ZIC2 in Mutant PC-3 Cells 
  In an effort to determine rescued phenotype of ZIC2 in PC-3 ZIC2 -/- cells, we 
transfected ZIC2 vector and made stable with selection. We have successfully recovered 
the cellular growth showing significance within the 7 day time course. ZIC2 -/-Z has an 
approximate cell growth approximately 3 times greater than -/-E control. The cell 
growth of ZIC2 -/-Z is shown to be significant. We also demonstrate real-time PCR 
analysis of gene targets (indirect and direct) with ZIC2-/- and ZIC2 -/-Z. Protein 
expression also eliminates the any off-target effects and supports restoration of ZIC2 as 
a tumor promoter. Our pathway analyses promote specific roles for ZIC2 in multiple 






4.10 Post-translational Investigation of ZIC2 Protein 
 Protein turnover is essential for homeostatic regulation of intracellular proteins. 
Generation and degradation is controlled by post-translational modifications. Mostly, 
protein degradation is controlled by ubiquitin mediated proteasome pathway. This 
pathway allows for mono- or poly- ubiquitination ligation to substrate by a class of 
enzymes, E3 ligases. Sumoylation is an additional post translational modification that has 
been reported to assist in protein stabilization and subsequent ubiquitin attachment. 
RNF180 is an E3 ligase with a molecular weight of 68 kDa. To date the predicted 
ubiquitination site within ZIC2 has not been identified. We hypothesize that the 
oncoprotein ZIC2 is targeted for degradation by the ubiquitin proteasome pathway via 
interaction with RNF180. To determine the necessity for the lysine residues upstream of 
the zinc fingers in the ZIC2 sequence, we sought to transiently overexpress ZIC2 with 
site-directed mutagenesis (Figure 21). 





Figure 21. (A) Transient transfection of ZIC2 K61R, K253R, and K61R+K253R. (B) Immunoprecipitation 
of ZIC2 K61R, K253R, and K61R+K253R interacting with Ub and RNF180.  
 
 We have examined the ZIC2 protein expression in PC-3 cells overexpressing 
ZIC2 K-R plasmids. It is exhibited that ZIC2 is not degraded when the K61R position is 
compromised. Sumoylation at the K253R position is abolished however ubiquitination is 
a viable PTM. Altering both lysine residues aids in the stabilization or increased 
expression because both positions are compromised. ZIC2 has a role as a transcriptional 
regulator in the nucleus. In order to determine the nuclear localization of K-R 
mutagenesis, we assessed the localization by immunofluorescence (Figure 22). The 
nuclear localization was not altered. Immunoprecipitation of ZIC2 overexpression vectors 
with site-directed mutagenesis was achieved by precipitation of MYC-DDK tagged ZIC2 
(WT, K61, K253, and K61+K253) and immunoblotted with Ub and RNF180 antibodies. 
Ubiquitin interaction was observed in the ZIC2 WT overexpression and K253R. This 






exposed a different position necessary for interaction with the E3 ligase. The K253 
position compromised an interaction with RNF180 while the ZIC2 WT and K61 
displayed an interaction with RNF180.  
 
Figure 22. Immunofluorescence analysis of K-R mutation does not inhibit nuclear localization of ZIC2-
Myc. Modifications of Lysine residues upstream of zinc fingers show that localization of ZIC2 is not 










 This study highlights aberrant expression of ZIC2 in prostate cancer that 
contributes to the worsened progression. We have provided evidence of ZIC2 being 
aberrantly expressed in prostate cancer samples of the cancer genome atlas database. This 
gene expression data along with an initial study of ZIC2 by Tomlins et al. thrusted us to 
elucidate the role for ZIC2 in prostate cancer. 
  To establish in vitro models for investigating ZIC2 function in prostate cancer, we 
identified ZIC2 expression by immunoblot in multiple prostate cancer cell lines. ZIC2 
protein was found to be expressed in all prostate cancer cell lines examined.  One 
significant observation from our data is the detection of differing patterns of ZIC2 protein 
bands between the AR positive and AR negative cell lines.   In all cell lines, we observe a 
protein with a molecular weight just above 65kDa. This difference in molecular weight, 
from the predicted 55kDa for ZIC2, suggests the occurrence of post-translational 
modifications.  Previous studies have identified phosphorylation of ZIC2 at amino acid 
S191 and S200, but an altered protein migration patterns was not observed in those 
studies. From our identification of ZIC2 expression in prostate cancer cell lines, we chose 
PC-3 cells for further study due to their aggressive cancer phenotype including their 




cell lines, we employed CRISPR-Cas9 gene editing of ZIC2 in PC-3. PC-3 ZIC2 -/- cells 
show altered expression of ZIC2 and significantly decreased proliferation rates when 
compared to the PC-3 parental cells.  Additionally, siRNA mediated ZIC2 knockdown 
induced cell apoptosis while ZIC2 overexpression enhanced proliferation in pancreatic 
cancer cells.35  The reduced proliferation rate in ZIC2 -/- cells that we report here also 
suggest a possible increase in apoptosis or senescence in prostate cancer when ZIC2 
levels are altered.   
 We also present data indicating that ZIC2 promotes metastasis in lethal prostate 
cancer.  Here, we report that migration and invasion capabilities of PC-3 ZIC2 -/- cells 
were significantly reduced when compared to PC-3 parental cells.  These assays are used 
as in vitro models to measure the metastatic potential of cancer cells, a hallmark of 
aggressive lethal prostate cancer.  In a completely different context, ZIC2 was recently 
shown to control the migration of neurons within the developing mouse forebrain.33 This 
observation, along with our findings strengthens the connection between ZIC2 expression 
and cell migration.  
 Furthermore we also highlight the migration and invasion potential of PC-3 
ZIC2 -/- cells. The migration and invasion was significantly deterred by ZIC2 
knockdown. However, PZ cells did not significantly have the migration potential greater 
than the PE control. This could be a result of PZ cells undergoing cellular division in 
opposition to migration. We did see the invasion potential significantly increase in the PZ 




forebrain.33 This along with our studies contributes the role ZIC2 may have in cell 
migration.  
 We expected to observe an undersized S phase due to the significant increase of 
the cell proliferation of PZ cells. The distinct changes in phases from one to the next was 
not completely captured due to the hypothesized speed of a complete cell cycle in PZ 
cells  progressing  double or triple replications and divisions compared to a single 
division of the wild-type.  Traditionally, cyclin dependent kinase inhibitors have been 
well studied as negative regulators of the cell cycle. CDKN1B, specifically, has a specific 
role in G1/S phase transition. It is hypothesized that the normal activity of CDKN1B 
assists the cell into S phase entry. Our overlapping analysis from IPA displays CDKN1B 
involvement however it is necessary to understand the Restriction point within cancer 
cells is dysregulated. Thus, proceeding into S phase is not rescued by the Restriction 
point due to S phase promoting factor. CCNA1 which is also significantly downregulated 
supports a role for the PC-3 ZIC2 -/- cell to proceed through G1 but replication is delayed 
to the downregulation of CCNA1. Our proliferation growth curves do not support 
immediate programmed cell death but possibly senescent activity for the cell to remain 
proliferative.  
We have utilized RNA-Seq to evaluate several genetic alterations in the oxidative 
phosphorylation pathway. One gene in particular, MT-CO3, was significantly upregulated 
in the ZIC2 knockdown model. MT-CO3 operates in Complex IV of the oxidative 
phosphorylation pathway. We highlight the metabolic switch in PC-3 cells using the 




results thus far promote ZIC2 as an oncoprotein. We have noticed a significant decrease 
in the cell proliferation of the ZIC2 knockdown cells compared to the wild-type PC-3 
cells.  Introduction of ZIC2 as proof of concept rescue implicated contrasting results and 
allowed a metabolic switch identified by the MTS assy. Although the mechanism of how 
aberrant expression of ZIC2 suppresses oxidative phosphorylation remains to be 
elucidated, we provide evidence that ZIC2 expression aids in the control of mitochondrial 
dysfunction in PC-3 cells.  
 Our data revealed an unexpected significant increase in metabolic activity in the 
slower growing PC-3 ZIC2 -/- cells as measured by the MTS assay. We suggest this 
increase in metabolism in PC-3 ZIC2 -/- cells is in part due to recovered oxidative 
phosphorylation in the mitochondria of PC-3 ZIC2 -/- cells revealed by increased MT-
CO3 expression.  Re-introduction of ZIC2 into these cells was able to significantly lower 
both MT-CO3 expression and MTS assay activity.  We propose that ZIC2 contributes to 
mitochondrial dysfunction in PC-3 cells promoting the Warburg effect and that loss of 
ZIC2 in PC-3 ZIC2 -/- cells contributes to an increased preference for energy production 
by mitochondrial oxidative phosphorylation.  Data recently reported indicating that that 
CD44 expression in PC-3 cells is correlated with increased glycolysis and reduced 
oxidative phosphorylation may provide a link between ZIC2 and mitochondrial function.  
CD44 mRNA levels are significantly reduced in our PC-3 ZIC2 -/- cells suggesting ZIC2 
may activate CD44 expression.  The finding that ZIC2 is essential for transcriptional 




complex supports the idea that ZIC2 may act to upregulate pro-oncogenic genes such as 
CD44, CCNA1, JUN and MMP13.   
 Specifically, we verified the transcriptional upregulation of two known tumor 
suppressors, KISS1 and DKK3, in PC-3 ZIC2 -/- cells.  As its name implies, the peptide 
ligand KiSS-1 metastasis-suppressor (KISS1), acts as a metastasis suppressor in 
malignant melanomas, esophageal squamous cell, ovarian  and bladder cancers  through 
interaction with its G-protein coupled receptor.74-75,76  Our data indicate that upregulation 
of KISS1 is correlated with a loss of proliferation, migration and invasion in PC-3  
ZIC2 -/- cells, which supports a metastasis-suppressor role for KISS1 in prostate cancer. 
Aberrant Wnt signaling has been reported in many cancer models.  Data that links ZIC2 
to Wnt signaling was reported in a vertebrate model of embryonic development where 
ZIC2 was shown to bind to TCF4, resulting in restricted β-catenin nuclear translocation.  
DKK3, a potent Wnt signaling inhibitor, acts as a tumor suppressor by disrupting the 
FZD/LRP5/LRP6 receptor complex that is required for canonical WNT signaling.  Our 
data indicating significant upregulation DKK3 in PC-3 ZIC2 -/- cells supports the notion 
that DKK3 is also tumor suppressor in prostate cancer.  This is consistent with other 
reports of DKK3 expression in the normal epithelium of the prostate being lost during 
benign and malignant transformation.   Interestingly, there are conserved ZIC2 DNA 
binding site motifs (5’-GGTGGTC-3’) near the TSS of both DKK3 and KISS1.11  
Therefore, ZIC2 could conceivably function as part of a transcriptional co-repressor 
complex bound near the TSS of these tumor suppressor genes to downregulate their 




 TMPRSS2 is found fused to ERG in ~50% of all prostate cancers.  TMPRSS2 
fusions to several ETS transcription factors, including ERG, are thought to promote 
prostate cancer initiation when cells are androgen sensitive and AR positive.  Here we 
report that the androgen regulated gene, TMPRSS2, was significantly upregulated in PC-3 
ZIC2-/- cells.  The parental PC-3 cells are known to be AR negative as well as androgen 
insensitive.65  This suggests that some aspect of hormone regulated gene expression is 
compromised when ZIC2 is present and that hormone regulated gene expression is 
restored in PC-3 ZIC2 -/- cells as evidenced by TMPRSS2 re-expression. The 
upregulation of TMPRSS2 in PC3 ZIC2 -/- cells suggests that these cells may have re-
acquired sensitivity to hormone deprivation, a trait that is ultimately lost in castration 
resistant prostate cancer (CRPC).    
 We have achieved the conclusion that ZIC2 knockdown in vitro mediates several 
cellular processes associated with PC-3 cells. Further studies should be done to determine 
the key gene targets of ZIC2 transcriptional regulation. An oncoprotein is described as a 
protein that influences cancer progression beyond the transcriptional level. We provide 
functional characteristics and molecular biology rationale for the addition of ZIC2 into 
the oncoprotein category. The main goal in establishing post-translational products of 
ZIC2 was to provide reasonable evidence for the aberrant expression of ZIC2 in prostate 
cancer. By introduction of K-R mutations, we first assessed transient expression of ZIC2. 
It was observed that K61R was not degraded in contrast to the K253R. This persuaded us 
to perform immunoprecipitation of ZIC2 and the predicted PTM- ubiquitination and 




necessary for interaction with RNF180. Overall we have supported previous work to 
describe the interaction of ZIC2 and RNF180 within the first 255 amino acids of the 
ZIC2 sequence.  
In vitro modeling in PC-3 cells was successful in proving the hypothesis that 
aberrant expression effects prostate cancer progression. We present Figure 23 as the 
working model for ZIC2 contributing to prostate cancer progression. Future studies 
corroborating ZIC2 will be achieved using alternative prostate cancer cell lines in vitro 
and in vivo modeling to establish therapeutic and clinical relevance of disrupting aberrant 
expression of ZIC2.  
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